GlassScriptPhysician profile
Lindsay Choate
NPI 1760851521
$24,282.03
in general payments reported to CMS, 2019-2025
61 companies · $4,055 in 2025
The $4,055 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $6,888 · 2022: $4,801 · 2023: $4,404 · 2024: $4,134 · 2025: $4,055.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,483.13 |
| Education | $109.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $4,973.98 | 2021-2025 | Omnipod |
| Novo Nordisk INC | $2,416.84 | 2021-2025 | Ozempic, Rybelsus, Tresiba |
| Abbott Laboratories | $1,136.56 | 2021-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,111.37 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Amneal Pharmaceuticals LLC | $1,052.95 | 2021-2025 | Unithroid |
| Amgen INC. | $945.75 | 2021-2025 | Evenity, Prolia, Repatha |
| Dexcom, INC. | $921.89 | 2021-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $857.35 | 2021-2024 | Farxiga, Lokelma |
| Mannkind Corporation | $833.54 | 2021-2025 | Afrezza |
| Lilly USA, LLC | $830.09 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $738.21 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $667.35 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $648.92 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Antares Pharma, INC. | $455.42 | 2021-2025 | Xyosted, Nocdurna, Tlando |
| Corcept Therapeutics | $441.99 | 2022-2025 | Korlym |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $428.66 | 2022-2025 | Minimed 780g, Intellis Adaptivestim |
| Ibsa Pharma INC. | $398.97 | 2022-2025 | Tirosint, Tirosint, Licart |
| Amarin Pharma, INC. | $356.87 | 2021-2023 | |
| Tandem Diabetes Care, INC. | $336.17 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Radius Health, INC. | $302.44 | 2021-2025 | Tymlos |
| Abbvie INC. | $297.78 | 2021-2025 | |
| Cequr Corporation | $289.71 | 2024-2025 | Cequr Simplicity |
| Alexion Pharmaceuticals, INC. | $288.69 | 2022-2025 | Strensiq |
| Merck Sharp & Dohme LLC | $288.14 | 2021-2023 | Steglatro, Steglujan |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $281.52 | 2021-2024 | Cycloset |
| Madrigal Pharmaceuticals | $272.80 | 2024-2025 | Rezdiffra, Resmetirom |
| Novartis Pharmaceuticals Corporation | $260.71 | 2021-2025 | |
| Currax Pharmaceuticals LLC | $226.71 | 2022-2025 | Contrave, Nexletol, Nexlizet |
| Endo Pharmaceuticals INC. | $207.76 | 2021-2023 | Aveed |
| Avvisto Therapeutics, LLC | $204.80 | 2024-2025 | Cycloset |
| Clarus Therapeutics INC. | $192.79 | 2021 | |
| Horizon Therapeutics Plc | $153.69 | 2021-2022 | |
| Vistapharm, INC. | $140.50 | 2021 | |
| Ascendis Pharma Endocrinology INC | $125.29 | 2025 | Yorvipath |
| Bausch Health US, LLC | $107.14 | 2022-2024 | Aplenzin, Wellbutrin |
| Zealand Pharma US, INC. | $101.93 | 2022 | |
| Ascensia Diabetes Care US INC. | $101.70 | 2023-2024 | |
| Beta Bionics, INC. | $101.10 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Recordati_rare_diseases_inc. | $89.97 | 2024-2025 | Isturisa, Signifor Lar |
| Halozyme INC | $72.20 | 2023 | |
| Sequel Med Tech, LLC | $71.49 | 2025 | Twiist |
| Esperion Therapeutics, INC. | $66.54 | 2021-2025 | Nexletol |
| Rhythm Pharmaceuticals, INC. | $59.42 | 2025 | Imcivree |
| Acerus Pharmaceuticals Corporation | $45.07 | 2021 | |
| Vivus LLC | $38.48 | 2021-2024 | Qsymia |
| Tolmar, INC. | $38.37 | 2025 | Jatenzo |
| Scynexis, INC. | $31.71 | 2022 | |
| Astellas Pharma US INC | $26.00 | 2025 | Veozah |
| Neurocrine Biosciences, INC. | $25.90 | 2025 | |
| Opko Pharmaceuticals, LLC | $25.81 | 2024 | Rayaldee |
| Kowa Pharmaceuticals America, INC. | $25.75 | 2021-2022 | |
| Embecta Corp. | $23.80 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Soleno Therapeutics, INC. | $21.76 | 2025 | Vykat Xr |
| Evoke Pharma, INC. | $18.76 | 2024 | |
| Kyowa Kirin, INC. | $18.37 | 2023 | Crysvita |
| Lifescan, INC. | $16.15 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $14.93 | 2025 | Evkeeza |
| Glaxosmithkline, LLC. | $14.04 | 2025 | Arexvy, Shingrix |
| Paratek Pharmaceuticals, INC. | $13.68 | 2023 | Nuzyra |
| Becton, Dickinson and Company | $12.90 | 2021 | |
| Smith+Nephew, INC. | $12.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsay Choate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.